News
GlaxoSmithKline’s gene therapy Strimvelis for the treatment of the ultra-rare ‘bubble baby syndrome’ has been approved by NICE. The one-off therapy costs €594,000, equivalent to £505,000 ...
A UK biotech start-up has gained a sought after ‘promising innovative medicine’ (PIM) designation for its ultra-rare disease gene therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback